NOXXON’s SDF-1 inhibitor NOX-A12 completes Phase I
14-Dec-2011
- Germany
Based on compelling pre-clinical data in hematological and solid tumors, NOXXON believes that NOX-A12 has the potential to be developed for treatment of multiple oncology indications. Initiation of the first Phase IIa trial of NOX-A12 in a hematological tumor indication is planned early in 2012, subject to regulatory and ethics committee approvals.
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.